U.S. flag

An official website of the United States government

NM_003238.6(TGFB2):c.305A>G (p.Glu102Gly) AND Loeys-Dietz syndrome 4

Germline classification:
Uncertain significance (1 submission)
Last evaluated:
Jun 23, 2023
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV001824448.15

Allele description [Variation Report for NM_003238.6(TGFB2):c.305A>G (p.Glu102Gly)]

NM_003238.6(TGFB2):c.305A>G (p.Glu102Gly)

Gene:
TGFB2:transforming growth factor beta 2 [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
1q41
Genomic location:
Preferred name:
NM_003238.6(TGFB2):c.305A>G (p.Glu102Gly)
HGVS:
  • NC_000001.11:g.218347006A>G
  • NG_027721.2:g.6673A>G
  • NM_001135599.4:c.305A>G
  • NM_003238.6:c.305A>GMANE SELECT
  • NP_001129071.1:p.Glu102Gly
  • NP_003229.1:p.Glu102Gly
  • NC_000001.10:g.218520348A>G
  • NR_138148.2:n.1671A>G
  • NR_138149.2:n.1671A>G
Protein change:
E102G
Links:
dbSNP: rs967581444
NCBI 1000 Genomes Browser:
rs967581444
Molecular consequence:
  • NM_001135599.4:c.305A>G - missense variant - [Sequence Ontology: SO:0001583]
  • NM_003238.6:c.305A>G - missense variant - [Sequence Ontology: SO:0001583]
  • NR_138148.2:n.1671A>G - non-coding transcript variant - [Sequence Ontology: SO:0001619]
  • NR_138149.2:n.1671A>G - non-coding transcript variant - [Sequence Ontology: SO:0001619]

Condition(s)

Name:
Loeys-Dietz syndrome 4 (LDS4)
Synonyms:
ANEURYSM, AORTIC AND CEREBRAL, WITH ARTERIAL TORTUOSITY AND SKELETAL MANIFESTATIONS
Identifiers:
MONDO: MONDO:0013897; MedGen: C3553762; OMIM: 614816

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV001567240Labcorp Genetics (formerly Invitae), Labcorp
criteria provided, single submitter

(Invitae Variant Classification Sherloc (09022015))
Uncertain significance
(Jun 23, 2023)
germlineclinical testing

PubMed (1)
[See all records that cite this PMID]

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria.

Nykamp K, Anderson M, Powers M, Garcia J, Herrera B, Ho YY, Kobayashi Y, Patil N, Thusberg J, Westbrook M; Invitae Clinical Genomics Group., Topper S.

Genet Med. 2017 Oct;19(10):1105-1117. doi: 10.1038/gim.2017.37. Epub 2017 May 11. Erratum in: Genet Med. 2020 Jan;22(1):240. doi: 10.1038/s41436-019-0624-9.

PubMed [citation]
PMID:
28492532
PMCID:
PMC5632818

Details of each submission

From Labcorp Genetics (formerly Invitae), Labcorp, SCV001567240.5

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)

Description

Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on TGFB2 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. ClinVar contains an entry for this variant (Variation ID: 1061180). This variant has not been reported in the literature in individuals affected with TGFB2-related conditions. The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This sequence change replaces glutamic acid, which is acidic and polar, with glycine, which is neutral and non-polar, at codon 102 of the TGFB2 protein (p.Glu102Gly).

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Oct 8, 2024